QUEBEC CITY, May 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today
that it has entered into an At Market Issuance ("ATM") Sales
Agreement, dated May 9, 2014, with
MLV & Co. LLC ("MLV"), under which the Company may, at its
discretion, from time to time during the term of the sales
agreement, sell up to a maximum of 14,018,692 million of its common
shares through ATM issuances on the NASDAQ Stock Market, up to an
aggregate amount of US $15 million.
MLV will act as sales agent for any sales made under the ATM. The
common shares will be sold at market prices prevailing at the time
of the sale of common shares, and, as a result, prices may
vary.
In connection with the execution of the ATM Sales Agreement with
MLV, the Company will file with the United States Securities and
Exchange Commission (the "SEC") a prospectus supplement to its
shelf registration statement on Form F-3, which was declared
effective by the SEC on March 28,
2014.
The shelf registration statement on Form F-3 and, when filed,
the supplement thereto, will be available on the SEC's website
(www.sec.gov). Alternatively, MLV will provide copies of these
documents upon request by contacting MLV & Co. LLC, Attention:
Randy Billhardt, 1251 Avenue of the
Americas, 41st Floor, New
York, NY 10020, or by calling 212-542-5882.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any of the common
shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds at
various stages of development. For more information please visit
www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.